Skip to content

The therapeutical effect of high-frequency repetitive transcranial magnetic stimulation on obstructive sleep apnea in stroke patients

The therapeutical effect of high-frequency repetitive transcranial magnetic stimulation on obstructive sleep apnea in stroke patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000031200
Enrollment
Unknown
Registered
2020-03-24
Start date
2020-04-01
Completion date
Unknown
Last updated
2020-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive sleep apnea

Interventions

therapy group:10Hz rTMS
Control group:No transcranial magnetic stimulation intervention

Sponsors

The First Affiliated Hospital of Nanhua University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with the first and unilateral stroke, meeting the diagnostic criteria of stroke, and the course of disease is less than 3 months; 2. Patients whose Epworth sleepiness score is more than 11, whose polysomnography (PSG) diagnosis is OSA, and whose AHI >=15 times/h; 3. Patients who are conscious and have stable vital signs at admission; 4. Patients and caregivers willing to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with upper airway structural diseases or abnormalities: jaw deformity, hypertrophy of turbinate, deviation of nasal septum, nasal polyp, tumor of nasopharynx, hypertrophy of tonsil III degree, adenoid hypertrophy, tumor after epiglottis, etc; 2. Patients with stroke involving cortex, a epilepsy history, first-degree relatives with epilepsy history and patients using epilepsy drugs; 3. Patients with severe cognitive impairment or inability to perform simple instructions; 4. Patients with pacemakers and metal implants; 5. Patients with skull defect in the stimulation area; 6. Patients with severe impairment of heart, lung, liver, kidney and other important organ functions.

Design outcomes

Primary

MeasureTime frame
Apnea Hyponea Index, AHI;

Secondary

MeasureTime frame
Mean SaO2, MSaO2;lowest SaO2, LSaO2;awake average genioglossus EMG;maximal genioglossus EMG;sleep onset average GGEMG;

Countries

China

Contacts

Public ContactQi Wu

The First Affiliated Hospital of Nanhua University

wuqi87@126.com+86 15200509157

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026